Toxicogenomics in predictive toxicology in drug development

被引:93
作者
Suter, L [1 ]
Babiss, LE
Wheeldon, EB
机构
[1] F Hoffmann La Roche & Co Ltd, Dept Nonclin Drug Safety, CH-4070 Basel, Switzerland
[2] F Hoffmann La Roche Inc, Dept Preclin R&D, Nutley, NJ 07110 USA
来源
CHEMISTRY & BIOLOGY | 2004年 / 11卷 / 02期
关键词
D O I
10.1016/j.chembiol.2004.02.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The goal of toxicology is the assessment of possible risk to man. An emerging technology with the potential to have a major impact on risk assessment is toxicogenomics. In this review, we provide an overview of the many possibilities for toxicogenomics including technology platforms, data interpretation, and regulatory perspective and we give examples of toxicogenomics investigations. Toxicogenomics is a powerful tool for compound classification, for mechanistic studies, and for the detection of toxicity markers. Thus, toxicogenomics helps in the extrapolation of findings across species and increases predictability. Biomarkers are valuable in the evaluation of compounds at earlier development phases, improving clinical candidate selection. Caution regarding the interpretation of the results is still necessary. Nevertheless, toxicogenomics will accelerate preclinical safety assessments and improve the prediction of toxic liabilities, as well as of potential risk accumulation for drug-drug or drug-disease interactions.
引用
收藏
页码:161 / 171
页数:11
相关论文
共 64 条
  • [1] Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies
    Aardema, MJ
    MacGregor, JT
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2002, 499 (01) : 13 - 25
  • [2] Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity
    Acuña G.
    Foernzler D.
    Leong D.
    Rabbia M.
    Smit R.
    Dorflinger E.
    Gasser R.
    Hoh J.
    Ott J.
    Borroni E.
    To Z.
    Thompson A.
    Li J.
    Hashimoto L.
    Lindpaintner K.
    [J]. The Pharmacogenomics Journal, 2002, 2 (5) : 327 - 334
  • [3] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [4] Advances in the pharmacogenomics of adverse drug reactions
    I Alvarado
    M-L Wong
    J Licinio
    [J]. The Pharmacogenomics Journal, 2002, 2 (5) : 273 - 273
  • [5] Selection bias in gene extraction on the basis of microarray gene-expression data
    Ambroise, C
    McLachlan, GJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) : 6562 - 6566
  • [6] AMIN R, 2004, IN PRESS ENV HLTH PE, V112
  • [7] Genomic interrogation of mechanism(s) underlying cellular responses to toxicants
    Amin, RP
    Hamadeh, HK
    Bushel, PR
    Bennett, L
    Afshari, CA
    Paules, RS
    [J]. TOXICOLOGY, 2002, 181 : 555 - 563
  • [8] BAKER V, 2004, IN PRESS ENV HLTH PE, V112
  • [9] Bartosiewicz MJ, 2001, J PHARMACOL EXP THER, V297, P895
  • [10] Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats:: Possible implications for toxicogenomics use of in vitro systems
    Boess, F
    Kamber, M
    Romer, S
    Gasser, R
    Muller, D
    Albertini, S
    Suter, L
    [J]. TOXICOLOGICAL SCIENCES, 2003, 73 (02) : 386 - 402